Socorro Pharmaceuticals

Socorro Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing innovative therapies for hard-to-treat cancers, with a primary emphasis on central nervous system (CNS) tumors. The company's lead candidate, SP-002, is a proprietary formulation of docetaxel designed to improve the delivery and efficacy of the drug across the blood-brain barrier. Socorro aims to address significant unmet medical needs in oncology, particularly glioblastoma multiforme, through advanced formulation science. The company leverages its expertise in drug delivery to optimize the pharmacokinetic profiles of established chemotherapeutic agents. Socorro is headquartered in New Jersey and operates as a private entity dedicated to improving outcomes for patients with aggressive malignancies.